Alkermes, Takeda Show Encouraging Data on Narcolepsy Drugs

Alkermes, Takeda show encouraging data on narcolepsy drugs

Alkermes and Takeda Pharmaceuticals said Monday that their respective drug candidates for a form of narcolepsy substantially helped patients stay awake, fueling the race to develop a new class of therapies that could transform sleep medicine. In a six-week Phase 2 trial, the highest dose of Alkermes’ treatment, alixorexton, helped increase the average amount of time patients stayed awake on a test by 26 minutes more than the changes experienced …

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 8, 2025-

Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market

Takeda met all endpoints in two Phase 3 trials of its orexin agonist oveporexton in narcolepsy type 1, bringing the Japanese drugmaker a step closer to a market that Wall Street says could generate sales of over $9 billion.